Viewing Study NCT04027868


Ignite Creation Date: 2025-12-24 @ 5:37 PM
Ignite Modification Date: 2026-01-21 @ 1:00 PM
Study NCT ID: NCT04027868
Status: COMPLETED
Last Update Posted: 2025-01-27
First Post: 2019-07-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Genomic BRCA and Extensive ovArian Cancer Testing
Sponsor: ARCAGY/ GINECO GROUP
Organization:

Study Overview

Official Title: Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities
Status: COMPLETED
Status Verified Date: 2025-01
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: GREAT
Brief Summary: This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.
Detailed Description: This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2019-A01190-57 OTHER ANSM View
19.06.45 OTHER Ethics Committee View